NGL FINECHEM
|
The Current P/E Ratio of NGL FINECHEM is 41.11.
Share Price | ₹2,542.6 | Apr 18,2024 |
Market Cap | ₹1,576.4 Cr | |
Earnings-TTM | ₹38.3 Cr | TTM-Consolidated Results |
Price/Earnings | 41.11x | Calculated as Market Cap/Earnings |
---|---|---|
Explore Stock Analytics |
Definition & Calculation of PE (Price/Earnings) ratio of NGL FINECHEM
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹1,576.4 Cr] as on Apr 18,2024
(/) Earnings [ ₹38.3 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 41.11x ]
Thus, for NGL FINECHEM , the investors are currently willing to pay 41.11 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of NGL FINECHEM !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of NGL FINECHEM over the last five years.
Historical PE (Price/Earnings) ratio chart of NGL FINECHEM
PE Ratio Performance Analysis for NGL FINECHEM
- NGL FINECHEM 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 22.19x.
- NGL FINECHEM 's operated at median p/e ratio of 19.28x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, NGL FINECHEM 's p/e ratio peaked in Mar2023 at 36.22x.
- NGL FINECHEM 's p/e ratio hit its five-year low in Mar2019 of 14.42x.
How does NGL FINECHEM 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
---|---|---|---|
NGL FINECHEM | 38.34 | 41.11 | 1,576.4 |
SUN PHARMACEUTICAL INDUSTRIES LTD | 8,998.63 | 40.45 | 364,015.0 |
CIPLA LTD | 3,744.03 | 29.06 | 108,809.0 |
DR REDDYS LABORATORIES LTD | 5,209.40 | 19.08 | 99,408.7 |
ZYDUS LIFESCIENCES LTD | 2,954.20 | 31.89 | 94,213.7 |
DIVIS LABORATORIES LTD | 1,382.97 | 71.36 | 98,684.0 |
MANKIND PHARMA LTD | 1,743.30 | 55.09 | 96,037.1 |
TORRENT PHARMACEUTICALS LTD | 1,494.00 | 57.71 | 86,219.0 |
LUPIN LTD | 1,809.74 | 40.13 | 72,621.1 |
AUROBINDO PHARMA LTD | 2,777.89 | 23.52 | 65,326.3 |
ABBOTT INDIA LTD | 1,145.58 | 48.33 | 55,366.4 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs NGL FINECHEM 's P/E Ratio
Top 10 Industry Peers | PE Ratio |
---|---|
Min industry PE | 19.08x |
Max industry PE | 71.36x |
Median industry PE | 40.45x |
Average industry PE | 41.61x |
You may also like the below Video Courses